Shares in Roivant Sciences Ltd. lost 2.7% on Friday, despite receiving U.S. regulatory approval for LISRAYA. The decline wiped out roughly $720 million in implied equity value.
Roivant Sciences (NASDAQ: ROIV) · Market data at August 28, 2026, 09:39:23 EDT
| Previous close | $37.58 |
| Friday open | $37.01 |
| Early range | $36.49–$37.13 |
| 52-week range | $11.85–$37.95 |
| Average volume | 5.36M shares |
| Measure | LISRAYA 30mg | Placebo |
|---|---|---|
| Mean TIS, week 52 | 46.5 | 31.2 |
| Advantage | +15.3 points | — |
| Treatment discontinuation | 6% | 11% |
| Trial size | 241 adults; 52 weeks | |
Peak-sales estimate as a share of current equity value
7.6% · $2.0B / $26.42B
| Cash and securities, June 30 | $3.9B |
| Quarterly net loss | $290.6M |
| Quarterly R&D | $202.0M |
| Quarterly revenue | $1.4M |
| Share repurchases | $208.7M |
| Event | Status | Investor test |
|---|---|---|
| FDA approval | Completed Aug. 27 | Regulatory risk removed |
| Specialty-pharmacy launch | Immediate | Prescription conversion |
| Pricing disclosure | Pending | Gross-to-net revenue |
| Payer coverage | Developing | Launch velocity and access |
Pricing remains undisclosed. Payer restrictions could slow uptake in a small patient population. LISRAYA carries boxed warnings for serious infections, malignancy, major cardiovascular events and thrombosis.
Sources: FDA, Roivant, Reuters, Roivant quarterly results and Google Finance. Trial and financial data are company-reported unless noted.
